I'm struggling to work out which hepatobiliary cancer patients you would actually use this product in. Extra hepatic cholangiocarcinoma is an infiltrative disease, and not particularly mass-forming which I'd have thought you'd need to inject Oncosil into. It is usually managed by stenting and you can use radio frequency ablation. Intrahepatic cholangiocarcinoma is not readily accessible to EUS injection. So, certainly not anything near 50% of patients might be candidates - closer to 1% I'd expect.
News: OSL Oncosil Medical Files For Registration Of Oncosiltm Device In U.S. Market, page-25
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $43.51M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $111.8K | 10.17M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 300000 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 7793598 | 12 |
View Market Depth
| Last trade - 11.50am 15/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |